51402 Federal Register / Vol. 76, No. 160 / Thursday, August 18, 2011 / Notices 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a), Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on May 16, 2011, Lin 

Zhi International Inc., 670 Almanor 

Avenue, Sunnyvale, California 94085, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the following basic 

classes of controlled substances: 

Drug Schedule 

Tetrahydrocannabinols (7370) ..... I 

3,4-Methylenedioxymethamphetamine (7405).I 

Cocaine (9041) ............................. II 

Oxycodone (9143) ........................ II 

Hydrocodone (9193) ..................... II 

Methadone (9250) ........................ II 

Dextropropoxyphene, bulk (nondosage forms) (9273).II 

Morphine (9300) ........................... II 

The company plans to manufacture 

the listed controlled substances as bulk 

reagents for use in drug abuse testing. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than October 17, 2011. 

Dated: August 8, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–21070 Filed 8–17–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated April 25, 2011, and 

published in the Federal Register on 

May 4, 2011, 76 FR 25375, Siemens 

Healthcare Diagnostics Inc., Attn: RA, 

100 GBC Drive, Mail Stop 514, Newark, 

Delaware 19702, made application by 

renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

a bulk manufacturer of the following 

basic classes of controlled substances: 

Drug Schedule 

Tetrahydrocannabinols (7370) ..... I 

Ecgonine (9180) ........................... II 

Morphine (9300) ........................... II 

The company plans to produce the 

listed controlled substances in bulk to 

be used in the manufacture of reagents 

and drug calibrator/controls which are 

DEA exempt products. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Siemens Healthcare Diagnostics Inc., to 

manufacture the listed basic classes of 

controlled substances is consistent with 

the public interest at this time. DEA has 

investigated Siemens Healthcare 

Diagnostics Inc., to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: August 9, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–21058 Filed 8–17–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated April 28, 2011, and 

published in the Federal Register on 

May 4, 2011, 76 FR 25376, Johnson 

Matthey Pharma Services, 70 Flagship 

Drive, North Andover, Massachusetts 

01845, made application by renewal to 

the Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of the following basic 

classes of controlled substances: 

Drug Schedule 

Amphetamine (1100) .................... II 

Methylphenidate (1724) ................ II 

Drug Schedule 

Hydrocodone (9193) ..................... II 

The company plans to utilize this 

facility to manufacture small quantities 

of the listed controlled substances in 

bulk and to conduct analytical testing in 

support of the company’s primary 

manufacturing facility in West Deptford, 

New Jersey. The controlled substances 

manufactured in bulk at this facility will 

be distributed to the company’s 

customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Johnson Matthey Pharma Services to 

manufacture the listed basic classes of 

controlled substances is consistent with 

the public interest at this time. DEA has 

investigated Johnson Matthey Pharma 

Services to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with state 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: August 10, 2011. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–21079 Filed 8–17–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated April 11, 2011, and 

published in the Federal Register on 

April 19, 2011, 76 FR 21916, Norac Inc., 

405 S. Motor Avenue, P.O. Box 577, 

Azusa, California 91702–3232, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the following basic classes of controlled 

substances: 

Drug Schedule 

Gamma Hydroxybutyric Acid 

(2010).

I 

mstockstill on DSK4VPTVN1PROD with NOTICES